<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Buserelin (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Buserelin (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Buserelin (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11287" href="/d/html/11287.html" rel="external">see "Buserelin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52865400"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Suprefact;</li>
<li>Suprefact Depot 2 Months;</li>
<li>Suprefact Depot 3 Months</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F4804466"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gonadotropin Releasing Hormone Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F4804497"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis</b>
<b>:</b>
<b>Intranasal:</b> 400 mcg (200 mcg into each nostril) 3 times daily; treatment duration is usually 6 months; maximum duration: 9 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13531fc0-f759-4ce8-adf1-0f2fb51f128a">Prostate cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b>
<b>Note:</b> Administration of an antiandrogen agent beginning ~7 days prior to initiation of buserelin therapy and continuing for up to ~4 to 5 weeks with buserelin therapy is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SubQ:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Suprefact: Initial: 500 mcg every 8 hours for 7 days. Maintenance: 200 mcg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Suprefact Depot:</p>
<p style="text-indent:-2em;margin-left:8em;">2-month: 6.3 mg implant every 2 months (dosage interval may be shortened or extended by a few days if needed).</p>
<p style="text-indent:-2em;margin-left:8em;">3-month: 9.45 mg implant every 3 months (dosage interval may be shortened or extended by a few days if needed).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal:</b> Maintenance: 400 mcg (200 mcg into each nostril) 3 times daily (after 7 days of initial SubQ treatment).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed doses:</i> Non-depot formulations: If a dose is missed, administer as soon as remembered; if it is almost time for the next dose, skip the missed dose and continue with regular dosing schedule. Do not double doses to make up for a missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990252"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987412"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F4804498"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F4804476"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults. Adverse reaction profile differs based on indication (endometriosis and prostate cancer) and route of administration. Incidences are reported for intranasal administration, unless otherwise noted as subcutaneous (SUBQ) solution or depot implant administration.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (implant: 2%; intranasal: 12%), heavy menstrual bleeding (24%), hot flash (implant: 16%; intranasal/SUBQ: 66% to 72%), loss of libido (intranasal: 75%; SUBQ: 85%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (males: implant: 2%; intranasal/SUBQ: 75% to 79%), vaginal dryness (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (implant: 1%; SUBQ: 12%; including irritation at injection site: 3%, pain at injection site: 5%, swelling at injection site: 3%, and urticaria at injection site: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (20% to 29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal mucosa irritation (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (implant: 1%; intranasal: 3% to 6%), hypertension (implant: 2%), palpitations (1%), peripheral edema (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (5%), diaphoresis (implant/intranasal: ≤2%), pruritus (implant/SUBQ: ≤1%), xeroderma (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (males: implant: &lt;1%; SUBQ: 3%), hirsutism (intranasal/SUBQ: ≤1%), menstrual disease (1%), weight gain (implant: &lt;1%; intranasal: 3%), weight loss (implant: &lt;1%; intranasal: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (implant/intranasal: ≤1%), diarrhea (intranasal: 8%; SUBQ: &lt;1%), dysgeusia (2%), gastrointestinal fullness (3%), nausea (implant/SUBQ: &lt;1%; intranasal: 7%), sore throat (5%), vomiting (4%), xerostomia (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dyspareunia (2%), mastalgia (females: 3%), vaginitis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Purpuric disease (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site reaction (intranasal: 5% to 7%: including application-site irritation: 4%, application-site pain, and urticaria [application-site]: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (1%), asthenia (implant: &lt;1%; intranasal: 7%), depression (implant: 2%; intranasal: 8%), dizziness (9%), emotional lability (7%), hostility (1%), insomnia (implant: &lt;1%; intranasal: 5%), malaise (8%), migraine (3%), nervousness (implant: &lt;1%; intranasal: 2%), pain (implant/SUBQ: ≤2%), paresthesia (2%), sleep disorder (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (5%), limb pain (2%), myalgia (2%), neck stiffness (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry nose (intranasal: 2%), rhinitis (2%), upper respiratory tract infection (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure (implant), syncope, tachycardia (implant), thrombophlebitis (implant), vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin photosensitivity, skin rash (implant/intranasal)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Exacerbation of diabetes mellitus (implant), feminization (males: SUBQ), hyperglycemia (implant)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, fecal incontinence (implant), gastrointestinal pain, increased appetite, oral mucosa ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast atrophy, breast hypertrophy, ejaculatory disorder (implant), genital pain (male: implant), genitourinary disease (implant), pelvic pain, urinary retention (SUBQ), vaginal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Myelofibrosis (implant)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bleeding at injection site (implant)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking, altered sense of smell, amnesia, drowsiness, hyperalgesia (implant), suicidal tendencies (implant), tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (implant), myopathy (implant)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, dry eye syndrome, transient blindness (one eye: implant)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (implant), epistaxis, pharyngitis (implant)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (implant/SUBQ)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any route of administration): Endocrine &amp; metabolic: Increased plasma estradiol concentration (transient), increased testosterone level (transient; with potential clinical flare: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any route of administration):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Lower extremity edema, prolonged QT interval on ECG, thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin reaction, eczema, hypertrichosis, loss of body hair, loss of scalp hair, onychia sicca</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Changes in serum lipids, decreased glucose tolerance, increased thirst, pituitary neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal pseudo-obstruction (Ohlsson 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Lactation (female), ovarian cyst (during initial phase of therapy), testicular atrophy</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue, lack of concentration, memory impairment, mood changes</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, decreased bone mineral density</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye disease, eye irritation, sensation of eye pressure, visual disturbance (including blurred vision)</p>
<p style="text-indent:2em;">Respiratory: Rhinorrhea</p></div>
<div class="block coi drugH1Div" id="F4804472"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to buserelin or any component of the formulation; patients who do not present with hormone-dependent prostate cancer; patients who have undergone orchiectomy.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasal solution: Additional contraindications: Undiagnosed abnormal vaginal bleeding; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F4804473"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: Testosterone suppression is associated with the development of anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). Patients with a history of depression should be monitored for mood changes and managed appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased bone density: <b> [Canadian Boxed Warning]: Prolonged use of a luteinizing hormone releasing hormone (LHRH) agonist may cause decreased bone mineral density and possibly lead to osteoporosis and increased risk of skeletal bone fracture.</b> Fracture risk increases with duration of therapy. Use of buserelin for &gt;6 months or in association with other risk factors may contribute to additional bone loss. Some clinical trial data suggest a partial reversibility of bone mineral loss following therapy discontinuation. Patients at risk for reduced bone density include those with chronic alcohol and/or tobacco use, family history of osteoporosis, and chronic treatment with antiseizure medications or corticosteroids. The benefits and risks of potential buserelin therapy should be considered before treatment is initiated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Disease flare: <b>[Canadian Boxed Warning]: A transient (usual duration &lt;10 days) exacerbation of the signs and symptoms of the disease process may be observed with the initiation of therapy.</b> Prostate cancer patients may experience worsening or new onset bone pain, neuropathy, hematuria, ureteral or bladder outlet obstruction, hydronephrosis, lymphostasis, or thrombosis with pulmonary embolus; cases of spinal cord compression possibly contributing to paralysis with or without complications have also been reported. Caution and close monitoring should be used in patients with vertebral metastases who are at risk for lesion exacerbation with possible spinal cord compression; Most buserelin studies were conducted without concomitant antiandrogen therapy, although in some studies, antiandrogen therapy was initiated 7 days prior to beginning buserelin and continued for 4 to 5 weeks with buserelin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including pruritus, rash, urticaria, allergic asthma with dyspnea, and local erythema) have been observed; anaphylactic/anaphylactoid shock have been reported rarely. Removal of buserelin depot implant may be necessary for severe reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypogonadism: Hypogonadism is an anticipated effect of androgen deprivation therapy; reversal of hypogonadism induced by therapy has not been established in this patient population.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pituitary adenoma: The development of pituitary adenomas may rarely be seen with long-term therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine 2010). Androgen deprivation may increase the QT interval (on ECG); avoid use in patients with congenital long QT syndrome; consider risk:benefit ratio in patients with concomitant antiarrhythmic therapy, electrolyte imbalances or heart failure. Correct electrolyte imbalances prior to initiation of therapy. Discontinue therapy if QT interval prolongation occurs. Increases in blood pressure (including hypertensive crisis) may occur in patients with preexisting hypertension; monitor blood pressure regularly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Reduced glucose tolerance and loss of blood glucose control have been noted in rare cases. Use caution in patients with diabetes; monitor blood glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometriosis: A transient exacerbation of the signs/symptoms may be associated with the initiation of therapy (worsening clinical condition may require discontinuation or surgical intervention). Oral contraceptives should be discontinued prior to starting therapy; use of a nonhormonal contraceptive is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary obstruction: In patients with prostate cancer, a transient increase in patient symptoms may occur early in therapy. Monitor for signs of urinary obstruction or retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: <b>[Canadian Boxed Warning]: Should be prescribed by a physician experienced in the use of hormonal therapy in endometriosis and prostate cancer, and administered under the supervision of a health care provider.</b></p></div>
<div class="block prod-avail drugH1Div" id="F11217372"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block dinfoc drugH1Div" id="F52865401"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprefact Depot 2 Months: 6.6 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprefact Depot 3 Months: 9.45 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprefact: 1 mg/mL ([DSC]) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprefact: 5.5 mg/5.5 mL (5.5 mL) [contains benzyl alcohol]</p></div>
<div class="block adm drugH1Div" id="F4804501"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b> Administer at equal time intervals; before first application, pump bottle several times in upright position until a uniform mist is released; priming may need to be repeated after storing between uses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SubQ:</b> Rotate injection sites; administer at equal time intervals.</p>
<p style="text-indent:-2em;margin-left:2em;">Depot formulation: Administer into lateral abdominal wall; a local anesthetic may be administered to injection site prior to implantation.</p></div>
<div class="block hazard drugH1Div" id="F49130917"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Buserelin may cause carcinogenicity, teratogenicity, reproductive toxicity, and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F239367"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b> Nasal solution: Treatment of endometriosis in patients who do not require surgical intervention as first-line therapy (length of therapy is usually 6 months and should not exceed 9 months).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b> Injection, nasal solution: Palliative treatment of hormone-dependent advanced prostate cancer (stage D).</p></div>
<div class="block mst drugH1Div" id="F4806068"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Buserelin may be confused with goserelin, nafarelin, triptorelin.</p>
<p style="text-indent:-2em;margin-left:4em;">Suprefact may be confused with Suprane.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298911"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F4804483"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Flotufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of ADT on the performance of flotufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Androgen Deprivation Therapy Agents may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact of ADT on the performance of gallium Ga 68 PSMA-11 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Piflufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of ADT on the performance of piflufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095741"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to initiation. To exclude preexisting pregnancy, begin treatment on the first or second day of menses; if there is doubt, a pregnancy test is recommended. Ovulation may occur with a missed dose; in the event a patient conceives, therapy should be discontinued. Oral contraceptives should be discontinued prior to starting therapy; patients should employ a nonhormonal method of contraception during therapy.</p></div>
<div class="block pri drugH1Div" id="F4804469"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Buserelin is contraindicated in pregnant women.</p></div>
<div class="block brc drugH1Div" id="F21121941"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Buserelin is contraindicated in breastfeeding women.</p>
<p style="text-indent:-2em;margin-left:2em;">Small amounts of buserelin can be detected in breast milk. Contains benzyl alcohol, which has been associated with gasping syndrome in premature infants.</p></div>
<div class="block mop drugH1Div" id="F4804504"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor blood glucose levels (baseline then periodically thereafter in patients with diabetes). Monitor BP (regularly in hypertensive patients); monitor for mood changes or signs/symptoms of depression.</p>
<p style="text-indent:-2em;margin-left:2em;">Prostate cancer: Monitor serum testosterone levels (4 to 6 weeks after initiation of therapy and every 3 months thereafter), prostate-specific antigen, prostatic acid phosphatase, bone scan, signs/symptoms of obstructive uropathy (if indicated consider CT scan, IV pyelogram, or ultrasound); digital rectal exam; ECG (in patients at risk for QT prolongation); serum electrolytes (calcium, magnesium and potassium; baseline and then as indicated); cardiovascular risk assessment (prior to treatment).</p>
<p style="text-indent:-2em;margin-left:2em;">Endometriosis: Monitor serum estradiol levels.</p></div>
<div class="block pha drugH1Div" id="F4804487"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Synthetic peptide analog of gonadotropin hormone releasing hormone (GnRH) with a magnified GnRH agonist effect and an extended duration of activity. Following an initial rise in the pituitary gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), chronic administration of buserelin results in a sustained suppression of LH and FSH and interferes with the production of ovarian and testicular steroids. Eventually, a decline in gonadal steroids to castration levels is observed.</p></div>
<div class="block phk drugH1Div" id="F4804489"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: 3-month depot implant: Mean time until testosterone reached castrate levels: 10 days</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~15%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via peptidase to inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: 70% (non-depot formulation); Intranasal: 1% to 3%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: SubQ: Immediate release: 80 minutes; Depot implants: 20 to 30 days; Nasal: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 3-month depot: &lt;1 day</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~50% as unchanged drug); Feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49056127"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Suprefact depot</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Profact | Suprefact</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Suprecur | Suprefact</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Busarlin | Buselin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Suprecur</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Superfact</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Profact</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Suprefact depot</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Suprecur | Suprefact</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Profact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Buserelin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Suprefact depot</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Supremon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Suprefact</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Suprefact | Suprefact depot</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17241858">
<a name="17241858"></a>Bodil Ohlsson 1, Béla Veress, Sabina Janciauskiene, et al. Chronic intestinal pseudo-obstruction due to buserelin-induced formation of anti-GnRH antibodies. <i>Gastroenterology. </i>2007;132(1):45-51. doi: 10.1053/j.gastro.2006.10.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buserelin-united-states-not-available-drug-information/abstract-text/17241858/pubmed" id="17241858" target="_blank">17241858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124128">
<a name="20124128"></a>Levine GN, D’Amico AV, Berger P, et al, “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,” <i>Circulation</i>, 2010, 121:831-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buserelin-united-states-not-available-drug-information/abstract-text/20124128/pubmed" id="20124128" target="_blank">20124128</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Suprefact (buserelin) [product monograph]. Mississauga, Ontario, Canada: Xediton Pharmaceuticals Inc; June 2020.</div>
</li>
<li>
<div class="reference">
                  Suprefact Depot (buserelin) [product monograph]. Mississauga, Ontario, Canada: Xediton Pharmaceuticals Inc; June 2020.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8867 Version 127.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
